Homotaurine
| |
| |
| Names | |
|---|---|
| Preferred IUPAC name
3-Aminopropane-1-sulfonic acid | |
| Other names
Tramiprosate; Alzhemed; 3-APS
| |
| Identifiers | |
3D model (
JSmol ) |
|
| ChEBI | |
| ChEMBL | |
| ChemSpider | |
| DrugBank | |
ECHA InfoCard
|
100.020.889 |
| EC Number |
|
| KEGG | |
PubChem CID
|
|
| UNII | |
CompTox Dashboard (EPA)
|
|
| |
| |
| Properties | |
| C3H9NO3S | |
| Molar mass | 139.17 g·mol−1 |
| Melting point | 293 °C (559 °F; 566 K) (decomposition) |
| Hazards | |
| GHS labelling:[2] | |
| |
| Warning | |
| H315, H319, H335 | |
| P261, P264, P271, P280, P302+P352, P304+P340, P305+P351+P338, P312, P321, P332+P313, P337+P313, P362, P403+P233, P405, P501 | |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
| |
Homotaurine (also known as tramiprosate (
INN), 3-amino-1-propanesulfonic acid, or 3-APS) is a natural sulfonic acid found in seaweed.[3] It is analogous to taurine, but with an extra carbon in its chain. It has GABAergic activity, apparently by mimicking GABA, which it resembles.[4]
Homotaurine was investigated in a
Phase III clinical trial as a potential treatment for Alzheimer's disease (AD) that did not show efficacy. However, post-hoc analyses have shown positive and significant effects of homotaurine on secondary endpoints and subgroups of patients, including a reduction in hippocampal volume loss and lower decline in memory function in the overall cohort, as well as a reduction in global cognitive decline in APOE4 allele carriers, suggesting a disease-modifying effect.[5] A study in cognitive impairment done in 2018 did show positive benefits.[6]
Homotaurine is currently in a phase 3 study with expected FDA approval as the first disease modifying drug for AD.[7][8]
Medical use
Acamprosate (N-acetyl homotaurine) was approved by the FDA in 2004 to treat alcohol dependence.[4]
Biochemical properties
In preclinical studies it had been found to bind to soluble
hypothermic activity.[10]
Homotaurine has been reported as a
GABA antagonist,[4] as well as a GABA agonist.[10][11] In vitro studies have found that homotaurine is a GABAA partial agonist[12] as well as a GABAB receptor partial agonist with low efficacy, becoming an antagonist and displacing the full agonists GABA and baclofen at this receptor.[13] In a study in rats, homotaurine reversed the catatonia induced by baclofen (the prototypical GABAB agonist),[14] and was able to produce analgesia via the GABAB receptor, an effect that was abolished when CGP-35348, a GABAB receptor antagonist was applied.[15][16]
In a human study homotaurine selectively and fully inhibits the formation of Aβ42 oligomers at the clinical dose, without evidence of vasogenic edema.[7]
One study in rats showed that homotaurine suppressed ethanol-stimulated dopamine release, as well as ethanol intake and preference in rats in a way similar to the N-acetyl derivative of homotaurine, acamprosate.[17]
References
- ^ "Homotaurine". Sigma-Aldrich.
- ^ "Tramiprosate". pubchem.ncbi.nlm.nih.gov. Retrieved 13 December 2021.
- PMID 25295005.
- ^ ISBN 978-0-470-18066-2.
- ^ S2CID 10816430.
- ^ Martorana, A.; Motta, C; Koch, G.; Massaia, M.; Mondino, S.; Raniero, I.; Vacca, A.; Di Lorenzo, F.; Cavallo, G.; Oddenino, E.; Pavanelli, E.; Maniscalco, M.; Montano, V.; Mastropietro, A.; Bellia, N. C.; Ciravegna, E.; La Rocca, M.; Vitale, E.; Lorico, F.; Zacchettin, B.; Scalise, A.; Codemo, A.; Gabelli, C.; Spano, M.; Poli, S.; Panuccio, D.; Bruno, P.; Alfieri, P.; Ruggiero, R.; Cursi, F.; Levi Della Vida, G. (15 March 2018). "Effect of homotaurine in patients with cognitive impairment: results from an Italian observational retrospective study". Journal of Gerontology and Geriatrics. 66: 15–20.
- ^ PMID 32787971.
- S2CID 44515548.
- PMID 17908052.
- ^ ISBN 978-1-4684-4367-7.
- ISBN 978-1-4511-1805-6.
- S2CID 10319072.
- PMID 6652358.
- S2CID 24010833.
- PMID 9510095.
- S2CID 19694376.
- PMID 11864639.